Proposing a scientific confidence framework to help support the application of adverse outcome pathways for regulatory purposes

Regulatory Toxicology and Pharmacology

Volumn 71, Issue 3, 2015, Pages 463-477

  Patlewicz, Grace ^a   Simon, Ted W ^b   Rowlands, J Craig ^c   Budinsky, Robert A ^c   Becker, Richard A ^d  

^a DUPONT COMPANY   (United States)

^b Ted Simon LLC   (United States)

^c DOW CHEMICAL COMPANY   (United States)

^d American Chemistry Council   (United States)

Author keywords

(Q)SAR; Adverse outcome pathway (AOP); Exposure:activity ratio (EAR); Integrated approaches to testing and assessment (IATA); Mode of action (MoA); Read across; Scientific confidence framework (SCF)

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; 3 INDOLEMETHANOL; AROMATIC HYDROCARBON RECEPTOR; POLYCYCLIC AROMATIC HYDROCARBON; CARCINOGEN; ENDOCRINE DISRUPTOR; ESTROGEN; IRRITANT AGENT;

ADVERSE OUTCOME PATHWAY; ARTICLE; CONCEPTUAL FRAMEWORK; ENVIRONMENTAL EXPOSURE; ESTROGEN ACTIVITY; GOVERNMENT REGULATION; HAZARD ASSESSMENT; HUMAN; LIVER TUMOR; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SCIENTIFIC CONFIDENCE FRAMEWORK; SKIN SENSITIZATION; TOXICOLOGICAL PARAMETERS; TUMOR PROMOTION; VALIDATION PROCESS; ANIMAL; BIOLOGICAL MODEL; CARCINOGEN TESTING; CHEMICALLY INDUCED; COMPUTER SIMULATION; DECISION SUPPORT SYSTEM; DOSE RESPONSE; DRUG APPROVAL; FACTUAL DATABASE; PROCEDURES; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STANDARDS; TOXICITY TESTING;

RODENTIA;

ANIMALS; CARCINOGENICITY TESTS; CARCINOGENS; COMPUTER SIMULATION; DATABASES, FACTUAL; DECISION SUPPORT TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG APPROVAL; ENDOCRINE DISRUPTORS; ESTROGENS; HUMANS; IRRITANTS; LIVER NEOPLASMS; MODELS, BIOLOGICAL; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RISK ASSESSMENT; SKIN IRRITANCY TESTS; TOXICITY TESTS;

EID: 84923590751     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2015.02.011     Document Type: Article

References (114)

1. Andersen M.E., Birnbaum L.S., Barton H.A., Eklund C.R. Regional hepatic CYP1A1 And CYP1A2 induction with 2,3,7,8-tetrachlorodibenzo-p-dioxin evaluated with a multicompartment genometric model of hepatic zonation. Toxicol. Appl. Pharmacol. 1997, 144:145-155.
2. Ankley G.T., Bennett R.S., Erickson R.J., Hoff D.J., Hornung M.W., Johnson R.D., Mount D.R., Nichols J.W., Russom C.L., Schmieder P.K., Serrrano J.A., Tietge J.E., Villeneuve D.L. Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ. Toxicol. Chem. 2010, 29:730-741. 10.1002/etc.34.
3. Aptula A.O., Patlewicz G.Y., Roberts D.W. Skin sensitisation: reaction mechanistic applicability domains for structure-activity relationships. Chem. Res. Toxicol. 2005, 18(9):1420-1426.
4. Aptula A.O., Roberts D.W. Mechanistic applicability domains for non animal-based prediction of toxicological end points: general principles and application to reactive toxicity. Chem. Res. Toxicol. 2006, 19:1097-1105.
5. Aylward L.L., Becker R.A., Kirman C.R., Hays S.M. Assessment of margin of exposure based on biomarkers in blood: an exploratory analysis. Regul. Toxicol. Pharmacol. 2011, 61:44-52. 10.1016/j.yrtph.2011.06.001.
6. Aylward L.L., Hays S.M. Consideration of dosimetry in evaluation of ToxCast™ data. J. Appl. Toxicol. 2011, 31:741-751. 10.1002/jat.1626.
7. Ball N., Bartels M.J., Budinsky R.A., Klapacz J., Hayes S.M., Kirman C.R., Patlewicz G.Y. The challenge of using read-across within the EU REACH regulatory framework; how much uncertainty is too much? Dipropylene glycol methyl ether acetate, an exemplary case study. Regul. Toxicol. Pharmacol. 2014, 68:212-221.
8. Bauch C., Kolle S.N., Ramirez T., Eltze T., Fabian E., Mehling A., Teubner W., van Ravenzwaay B., Landsiedel R. Putting the parts together: combining in vitro methods to test for skin sensitizing potentials. Regul. Toxicol. Pharmacol. 2012, 63:489-504. 10.1016/j.yrtph.2012.05.013.
9. Becker R.A., Hays S.M., Robison S., Aylward L.L. Development of screening tools for the interpretation of chemical biomonitoring data. J. Toxicol. 2012, 10.1155/2012/941082.
10. Becker, R.A., Rowlands, J.C., Patlewicz, G., Simon, T., 2014. Enhancing the Utility of T21 Assessment Methods by Employing a Scientific Confidence Framework and Exposure: Activity Profiling. Presented at ICCA-JRC Workshop, June 17-18, 2014 Lugano, Switzerland.
11. Becker R.A., Hays S.M., Kirman C.R., Aylward L.L., Wise K. Interpreting estrogen screening assays in the context of potency and human exposure relative to natural exposures to phytoestrogens. Birth Defects Res. B Dev. Reprod. Toxicol. 2014, 101:114-124. 10.1002/bdrb.21085.
12. Becker R.A., Paul K., Simon T.W., Marty S., Patlewicz G., Rowlands J.C. An exposure: activity profiling method for interpreting high-throughput screening data for estrogenic activity-proof of concept. Regul. Toxicol. Pharmacol. 2014, (submitted).
13. Becker, R.A., Budinsky, R.A., Patlewicz, G., Simon, T., Rowlands, C. 2015. The Adverse Outcome Pathway for Rodent Liver Tumor Promotion by Sustained Activation of the Aryl Hydrocarbon Receptor. in preparation.
14. Boutros P.C., Yao C.Q., Watson J.D., Wu A.H., Moffat I.D., Prokopec S.D., Smith A.B., Okey A.B., Pohjanvirta R. Hepatic transcriptomic response to TCDD in dioxin-sensitive and dioxin-resistant rats during the onset of toxicity. Toxicol. Appl. Pharmacol. 2011, 251:119-129.
15. Boverhof D.R., Burgoon L.D., Tashior C., Sharratt B., Chittim B., Harkema J.R., Mendrick D.L., Zacharewski T.R. Comparative toxicogenomic analysis of the hepatotoxic effects of TCDD in Sprague Dawley rats and C57BL/6 mice. Toxicol. Sci. 2006, 94:398-416.
16. Budinsky R.A., Schrenk D., Simon T., Van den Berg M., Maier A., Silkworth J.B., Lesa L.L., Brix A., Gasiewicz T., Kaminski N., Perdew G., Starr T.B., Walker N.J., Rowlands J.C. Mode of action and dose-response framework analysis for receptor-mediated toxicity: the aryl hydrocarbon receptor as a case study. Crit. Rev. Toxicol. 2014, 44:83-119. 10.3109/10408444.2013.835787.
17. Buist H., Aldenberg T., Batke M., Escher S., Klein Entink R., Kühne R., Marquart H., Pauné E., Rorije E., Schüürmann G., Kroese D. The OSIRIS weight of evidence approach: ITS mutagenicity and ITS carcinogenicity. Regul. Toxicol. Pharmacol. 2013, 67:170-181. 10.1016/j.yrtph.2013.01.002.
18. Cao F., Li X., Ye L., Xie Y., Wang X., Shi W., Zian X., Zhu Y., Yu H. Molecular docking, molecular dynamics simulation, and structure-based 3D_QSAR studies on the aryl hydrocarbon receptor agonistic activity of hydroxylated polychlorinated biphenyls. Environ. Toxicol. Pharmacol. 2013, 36:626-635.
19. Chang H., Wang Y.J., Chang L.W., Lin P. A histochemical and pathological study on the interrelationship between TCDD-induced AR expression, AhR activation, and hepatotoxicity in mice. J. Toxicol. Environ. Health Part A 2005, 68:1567-1579.
20. Chopra M., Schrenk D. Dioxin toxicity, aryl hydrocarbon receptor signaling, and apoptosis-persistent pollutants affect programmed cell death. Crit. Rev. Toxicol. 2011, 10.3109/10408444.2010.524635.
21. Cohen Hubal E.A., Richard A., Aylward L., Edwards S., Gallagher J., Goldsmith M.R., Isukapalli S., Tornero-Velez R., Weber E., Kavlock R. Advancing exposure characterization for chemical evaluation and risk assessment. J. Toxicol. Environ. Health B Crit. Rev. 2010, 13:299-313.
22. Conolly R.B., Andersen M.E. Hepatic foci in rats after diethylnitrosamine initiation and 2,3,7,8-tetrachlorodibenzo-p-dioxin promotion: evaluation of a quantitative two-cell model and of CYP 1A1/1A2 as a dosimeter. Toxicol. Appl. Pharmacol. 1997, 146:281-293.
23. Cox L.A., Douglas D., Marty S., Rowlands J.C., Patlewicz G., Goyak K.O., Becker R.A. Applying a scientific confidence framework to a HTS-derived prediction model for endocrine endpoints: lessons learned from a case study. Regul. Toxicol. Pharmacol. 2014, 69:443-450.
24. Denison M.S., Soshilov A.A., He G., DeGroot D.E., Zhao B. Exactly the same but different: promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin) receptor. Toxicol. Sci. 2011, 124:1-22. 10.1093/toxsci/kfr218.
25. Drewe, W.C., Cayley, A., Benz, R., Kruhlak, N.L., Surfraz, B. Identification of Adverse Outcome Pathways for the Nephrotoxicity of Nucleoside and Nucleotide Antiviral Drugs. Presented at the Society of Toxicology, March 24-27, Phoenix, AZ, USA.
26. Dupuis G., Benezra C. Allergic Contact Dermatitis to Simple Chemicals: a Molecular Approach 1982, Dekker, New York and Basel.
27. ECHA. 2008. Guidance on information requirements and chemical safety assessment. Chapter R.7a: Endpoint Specific Guidance. Available at < >. http://guidance.echa.europa.eu/docs/guidance:document/information_requirements_r7a_en.pdf?vers=20_08_08.
28. ECETOC. 2012. Technical Report 116 Category approaches, read-across, (Q)SAR available at < >. http://www.ecetoc.org/technical-reports.
29. Emter R., Ellis G., Natsch A. Performance of a novel keratinocyte-based reporter cell line to screen skin sensitizers in vitro. Toxicol. Appl. Pharmacol. 2010, 245:281-290. 10.1016/j.taap.2010.03.009.
30. Emter R., van der Veen J.W., Adamson G., Ezendam J., van Loveren H., Natsch A. Gene expression changes induced by skin sensitizers in the KeratinoSens™ cell line: discriminating Nrf2-dependent and Nrf2-independent events. Toxicol. In Vitro 2013, 27:2225-2232. 10.1016/j.tiv.2013.09.009.
31. European Commission, (EC) November 11, 2009. Regulation (EC) No. 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
32. Fielden M.R., Nie A., McMillian M., Elangbam C.S., Trela B.A., Yang Y., Dunn R.T., Dragan Y., Fransson-Stehen R., Bogdanffy M., Adams S.P., Foster W.R., Chen S.J., Rossi P., Kasper P., Jacobson-Kram D., Tatsuoka K.S., Wier P.J., Gollub J., Halbert D.N., Roter A., Young J.K., Sina J.F., Marlowe J., Martus H.J., Aubrecht J., Olaharski A.J., Roome N., Nioi P., Pardo I., Snyder R., Perry R., Lord P., Mattes W., Car B.D., Predictive Safety Testing Consortium, Carcinogenicity Working Group Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the rat. Toxicol. Sci. 2008, 103:28-34.
33. Fletcher N., Wahlstrom D., Lundberg R., Nilsson C.B., Nilsson K.C., Stockling K., Hellmold H., Hakansson H. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) alters mRNA expression of critical genes associated with cholesterol metabolism, bile acid biosynthesis, and bile transport in rat liver: a microarray study. Toxicol. Appl. Pharmacol. 2005, 207:1-24.
34. Forgac A.L., Kent M.N., Makley M.K., Mets B., DelRaso N., Jahns G.L., Burgoon L.D., Reo N.V., Zacharewski T.R. Comparative metabolomic and genomic analyses of TCDD-elicited metabolic disruption in mouse and rat liver. Toxicol. Sci. 2012, 125:41-55.
35. Gerberick G.F., Vassallo J.D., Bailey R.E., Chaney J.G., Morrall S.W., Lepoittevin J.-P. Development of a peptide reactivity assay for screening contact allergens. Toxicol. Sci. 2004, 81:332-343.
36. Gerberick G.F., Vassallo J.D., Foertsch L.M., Price B.B., Chaney J.G., Lepoittevin J.-P. Quantification of chemical peptide reactivity for screening contact allergens: a classification tree model approach. Toxicol. Sci. 2007, 97:417-427. 10.1093/toxsci/kfm064.
37. Godfrey H.P., Baer K. The effect of physical and chemical properties of the sensitizing substance on the induction and elicitation of delayed contact hypersensitivity. J. Immunol. 1971, 106:431-441.
38. Goodman D.G., Sauer R.M. Hepatotoxicity and carcinogenicity in female Sprague-Dawley rats treated with 2,3,7,8-tetrachlorordibenzo-p-dioxin (TCDD): a Pathology Working Group reevaluation. Regul. Toxicol. Pharmacol. 1992, 15:245-252.
39. Hailey J.R., Walker N.J., Sells D.M., Brix A.E., Jokinen M.P., Nyska A. Classification of proliferative hepatocellular lesions in harlan sprague-dawley rats chronically exposed to dioxin-like compounds. Toxicol. Pathol. 2005, 33:165-174.
40. Hartung T., Blaauboer B.J., Bosgra S., Carney E., Coenen J., Conolly R.B., Corsini E., Green S., Faustman E.M., Gaspari A., Hayashi M., Wallace Hayes A., Hengstler J.G., Knudsen L.E., Knudsen T.B., McKim J.M., Pfaller W., Roggen E.L. An expert consortium review of the EC-commissioned report "alternative (non-animal) methods for cosmetics testing: current status and future prospects - 2010". ALTEX 2011, 28:183-209.
41. Heise T., Schug M., Storm D., Ellinger-Ziegelbauer H.J., Ahr H., Hellwig B., Rahnenfuhrer J., Ghallab A., Guenther G., Sisnaiske J., Reif R., Godoy P., Mielke H., Gundert-Remy U., Lampen A., Oberemm A.G., Hengstler J. In vitro - in vivo correlation of gene expression alterations induced by liver carcinogens. Curr. Med. Chem. 2012, 19:1721-1730.
42. Hengstler J.G., Foth H., Gebel T., Kramer P.-J., Lilienblum W., Schweinfurth H., Völkel W., Wollin K.-M., Gundert-Remy U. Critical evaluation of key evidence on the human health hazards of exposure to bisphenol A. Crit. Rev. Toxicol. 2011, 41:263-291. 10.3109/10408444.2011.558487.
43. Institute of Medicine (IOM). 2010. Evaluation of biomarkers and surrogate endpoints in chronic disease. ISBN: 978-0-309-15129-0.
44. Jaworska J., Harol A., Kern P.S., Gerberick G.F. Integrating non-animal test information into an adaptive testing strategy - skin sensitization proof of concept case. ALTEX 2011, 28:211-225.
45. Jaworska J., Dancik Y., Kern P., Gerberick F., Natsch A. Bayesian integrated testing strategy to assess skin sensitization potency: from theory to practice. J. Appl. Toxicol. 2013, 10.1002/jat.2869.
46. Julien E., Boobis A.R., Olin S.S., Ilsi Research Foundation Threshold Working Group The key events dose-response framework: a cross-disciplinary mode-of-action based approach to examining dose-response and thresholds. Crit. Rev. Food Sci. Nutr. 2009, 49:682-689. 10.1080/10408390903110692.
47. Kennedy G.D., Nukaya M., Moran S.M., Glover E., Weinberg S., Balbo S., Hecht S.S., Pitot H.C., Drinkwater N.R., Bradfield C.A. Liver tumor promotion by 2,3,7,8-tetrachlorodibenzo-p-dioxin is dependent on the aryl hydrocarbon receptor and TNF/IL-1 receptors. Toxicol. Sci. 2014, 140:135-143.
48. Landsteiner K., Jacobs J.L. Studies on the sensitisation of animals with simple chemicals III. J. Exp. Med. 1936, 64:625-639.
49. Lorber M., Patterson D., Huwe J., Kahn H. Evaluation of background exposures of Americans to dioxin-like compounds in the 1990s and the 2000s. Chemosphere 2009, 77:640-651.
50. Meek M.E. Recent developments in frameworks to consider human relevance of hypothesized modes of action for tumours in animals. Environ. Mol. Mutagen. 2008, 49:110-116. 10.1002/em.20369.
51. Meek M.E., Bucher J.R., Cohen S.M., Dellarco V., Hill R.N., Lehman-McKeeman L.D., Longfellow D.G., Pastoor T., Seed J., Patton D.E. A framework for human relevance analysis of information on carcinogenic modes of action. Crit. Rev. Toxicol. 2003, 33:591-653.
52. Meek M.E., Boobis A., Cote I., Dellarco V., Fotakis G., Munn S., Seed J., Vickers C. New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis. J. Appl. Toxicol. 2014, 34:1-18.
53. Meek M.E., Palermo C.M., Bachman A.N., North C.M., Lewis R.J. Mode of action human relevance (species concordance) framework: evolution of the Bradford Hill considerations and comparative analysis of weight of evidence. J. Appl. Toxicol. 2014, 34:595-606.
54. Moolgavkar S.H., Luebeck E.G., Buchmann A., Bock K.W. Quantitative analysis of enzyme-altered liver foci in rats initiated with diethylnitrosamine and promoted with 2,3,7,8-tetrachlorodibenzo-p-dioxin or 1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin. Toxicol. Appl. Pharmacol. 1996, 138:31-42.
55. Morgan R.E., van Staden C.J., Chen Y., Kalyanaraman N., Kalanzi J., Dunn R.T., Afshari C.A., Hamadeh H.K. A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol. Sci. 2013, 136:216-241. 10.1093/toxsci/kft176.
56. Murk A.J., Rijntjes E., Blaauboer B.J., Clewell R., Crofton K.M., Dingemans M.M., Furlow J.D., Kavlock R., Kohrle J., Opitz R., Traas T., Visser T.J., Xia M., Gutleb A.C. Mechanism-based testing strategy using in vitro approaches for identification of thyroid hormone disrupting chemicals. Toxicol. In Vitro 2013, 27:1320-1346.
57. National Research Council (NRC) Toxicity Testing in the 21st Century: A Vision and a Strategy 2007, National Academies Press, Washington, DC.
58. National Research Council Exposure Science in the 21st Century: a Vision and a Strategy 2012, The National Academies Press, Washington, DC.
59. National Toxicology Programme. 2014. Toxicology studies of indole-3-carbinol (CAS No. 700-06-1_in F33/N rats and B6C3F1/N mice and toxicology and carcinogenensis studies of indole-3-carbinol in Harlan Sprague Dawley rats and B6C3F1 mice. NTP Technical Report 584.
60. Natsch A., Ryan C.A., Foertsch L., Emter R., Jaworska J., Gerberick F., Kern P. A dataset on 145 chemicals tested in alternative assays for skin sensitization undergoing prevalidation. J. Appl. Toxicol. 2013, 10.1002/jat.2868.
61. Nguyen L.P., Bradfield C.A. The search for endogenous activators of the aryl hydrocarbon receptor. Chem. Res. Toxicol. 2008, 21:102-116.
62. Nukada Y., Miyazawa M., Kazutoshi S., Sakaguchi H., Nishiyama N. Data integration of non-animal tests for the development of a test battery to predict the skin sensitizing potential and potency of chemicals. Toxicol. In Vitro 2013, 27:609-618.
63. Organisation for Economic Cooperation and Development (OECD) The Adverse Outcome Pathway for Skin Sensitisation by Covalent Binding to Proteins: Part 1: Scientific Evidence 2012, OECD, Paris.
64. OECD. 2004. ENV/JM/MONO/(2004)24 < >. http://appli1.oecd.org/olis/2004doc.nsf/linkto/env-jm-mono(2004)24.
65. OECD. 2007. Guidance on grouping of chemicals. OECD Series on Testing and Assessment No. 80. Organisation for Economic Co-operation and Development, Paris, France.
66. OECD. 2011. OECD Series on Testing and Assessment Number 138. Report of the Workshop on Using Mechanistic Information in Forming Chemical Categories. ENV/JM/MONO(2011) 8. Organisation for Economic Co-operation and Development. Paris, France.
67. Organisation for Economic Cooperation and Development, (OECD) The Adverse Outcome Pathway for Skin Sensitisation by Covalent Binding to Proteins. Part 2: Use of the AOP to Develop Chemical Categories and Integrated Testing and Assessment Approaches 2012, OECD, Paris.
68. Organisation for Economic Cooperation and Development (OECD) Guidance Document on Developing and Assessing Adverse Outcome Pathways 2013, OECD, Paris.
69. OECD. 2014. Guidance on grouping of chemicals. OECD Series on Testing and Assessment No. 194. Organisation for Economic Co-operation and Development, Paris, France.
70. OECD. 2014b. How to use the Toolbox AOP workflow for Skin Sensitization. Accessible at <>. http://www.oecd.org/env/ehs/risk-assessment/Tutorial_1_How%20to%20use%20AOP%20for%20Skin%20sensitization_F_28012014.pdf.
71. OECD. 2015a. Test Guideline 442c. in chemico skin sensitisation. Direct Peptide Reactivity Assay (DPRA).
72. OECD. 2015b. Test Guideline 442d in vitro skin sensitisation. ARE-Nrf2 Luciferase test method.
73. Pande K., Moran S.M., Bradfield C.A. Aspects of dioxin toxicity are mediated by interleukin 1-like cytokines. Mol. Pharmacol. 2005, 67:1393-1398.
74. Pastoor T.P., Bachman A.N., Bell D.R., Cohen S.M., Dellarco M., Dewhurst I.C., Doe J.E., Doerrer N.G., Embry M.R., Hines R.N., Moretto A., Phillips R.D., Rowlands J.C., Tanir J.Y., Wolf D.C., Boobis A.R. A 21st century roadmap for human health risk assessment. Crit. Rev. Toxicol. 2014, 44(Suppl. 3):1-5. 10.3109/10408444.2014.931923.
75. Patlewicz G., Simon T., Goyak K., Phillips R.D., Rowlands J.C., Seidel S., Becker R.A. Use and validation of HT/HC assays to support 21st century toxicity evaluations. Regul. Toxicol. Pharmacol. 2013, 10.1016/j.yrtph.2012.12.008.
76. Patlewicz G., Ball N., Booth E.D., Hulzebos E., Zvinavashee E., Hennes C. Use of category approaches, read-across and (Q)SAR: general considerations. Regul. Toxicol. Pharmacol. 2013, 67:1-12.
77. Patlewicz G., Ball N., Becker R.A., Booth E.D., Cronin M.T.D., Kroese D., Steup D., Van Ravenzwaay B., Hartung T. Food for thought. . .. Read-across approaches - misconceptions, promises and challenges ahead. ALTEX 2014, 31:387-396.
78. Patlewicz G., Kuseva C., Mehmed A., Popova Y., Dimitrova G., Ellis G., Hunziker R., Kern P., Low L., Ringeissen S., Robert D.W., Mekenyan O. TIMES-SS - recent refinements as a result of an Industrial skin sensitisation consortium. SAR QSAR Environ. Res. 2014, 25:367-391.
79. Patlewicz G., Kuseva C., Kesova A., Popova I., Zhechev T., Pavlov T., Roberts D.W., Mekenyan O.M. Towards AOP application - implementation of an integrated approach to testing and assessment (IATA) into a pipeline tool for skin sensitization. Regul. Toxicol. Pharmacol. 2014, 69:529-545.
80. Pelkonen O., Tolonen A., Rousu T., Tursas L., Turpeinen M., Hokkanen J., Uusitalo J., Bouvier d'Yvoire M., Coecke S. Comparison of metabolic stability and metabolite identification of 55 ECVAM/ICCVAM validation compounds between human and rat liver homogenates and microsomes - a preliminary analysis. ALTEX 2009, 26:214-222.
81. Petkov P.I., Rowlands J.C., Budinsky R., Zhao B., Denison M.S., Mekenyan O. Mechanism-based common reactivity pattern (COREPA) modelling of aryl hydrocarbon receptor binding affinity. SAR QSAR Environ. Res. 2010, 21:187-214. 920009073 [pii]. 10.1080/10629360903570933.
82. Python F., Goebel C., Aeby P. Assessment of the U937 cell line for the detection of contact allergens. Toxicol. Appl. Pharmacol. 2007, 220:113-124.
83. Reisinger K., Hoffmann S., Alépée N., Ashikaga T., Barroso J., Elcombe C., Gellatly N., Galbiati V., Gibbs S., Groux H., Hibatallah J., Keller D., Kern P., Klaric M., Kolle S., Kuehnl J., Lambrechts N., Lindstedt M., Millet M., Martinozzi-Teissier S., Natsch A., Petersohn D., Pike I., Sakaguchi H., Schepky A., Tailhardat M., Templier M., van Vliet E., Maxwell G. Systematic evaluation of non-animal test methods for skin sensitisation safety assessment. Toxicol. In Vitro 2014, 29:259-270.
84. Roberts D.W., Aptula A.O., Patlewicz G., Pease C. Chemical reactivity indices and mechanism-based read across for non-animal based assessment of skin sensitization potential. J. Appl. Toxicol. 2008, 28:443-454.
85. Roberts D.W., Natsch A. High throughput kinetic profiling approach for covalent binding to peptides. Application to skin sensitising potency of Michael acceptor electrophiles. Chem. Res. Toxicol. 2009, 22:592-603.
86. Roberts D.W., Patlewicz G. Integrated testing and assessment approaches for skin sensitization: a commentary. J. Appl. Toxicol. 2014, 34:436-440.
87. Rorije E., Aldenberg T., Buist H., Kroese D., Schüürmann G. The OSIRIS weight of evidence approach: ITS for skin sensitisation. Regul. Toxicol. Pharmacol. 2013, 67:146-156. 10.1016/j.yrtph.2013.06.003.
88. Rotroff D.M., Wetmore B.A., Dix D.J., Ferguson S.S., Clewell H.J., Houck K.A., Lecluyse E.L., Andersen M.E., Judson R.S., Smith C.M., Sochaski M.A., Kavlock R.J., Boellmann F., Martin M.T., Reif D.M., Wambaugh J.F., Thomas R.S. Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol. Sci. 2010, 117:348-358.
89. Rotroff D.M., Dix D.J., Houck K.A., Knudsen T.B., Martin M.T., McLaurin K.W., Reif D.M., Crofton K.M., Singh A.V., Xia M., Huang R., Judson R.S. Using in vitro high throughput screening assays to identify potential endocrine disrupting chemicals. Environ. Health Perspect. 2013, 121:7-14.
90. Rowlands J.C., Budinsky R., Gollapudi B., Novak R., Abdelmegeed M., Cukovic D., Dombokowski A. Transcriptional profiles induced by the aryl hydrocarbon receptor agonists 2,3,7,8-tetrachlorodibenz-p-dioxin, 2,3,7,8-tetrachlorodibenzofuran and 2,3,4,7,8-pentachlorodibenzofuran in primary rat hepatocytes. Chemosphere 2011, 85:232-238.
91. Sakaguchi H., Ashikaga T., Kosaka N., Sono S., Nishiyama N., Itagaki H. The in vitro skin sensitization test; human cell line activation test (h-CLAT) using THP-1 cells. Toxicol. Lett. 2007, 172:S93.
92. Scholz S., Sela E., Blaha L., Braunbeck T., Galay-Burgos M., García-Franco M., Guinea J., Klüver N., Schirmer K., Tanneberger K., Tobor-Kapłon M., Witters H., Belanger S., Benfenati E., Creton S., Cronin M.T.D., Eggen R.I.L., Embry M., Ekman D., Gourmelon A., Halder M., Hardy B., Hartung T., Hubesch B., Jungmann D., Lampi M.A., Lee L., Léonard M., Küster E., Lillicrap A., Luckenbach T., Murk A.J., Navas J.M., Peijnenburg W., Repetto G., Salinas E., Schüürmann G., Spielmann H., Tollefsen K.E., Walter-Rohde S., Whale G., Wheeler J.R., Winter M.J. A European perspective on alternatives to animal testing for environmental hazard identification and risk assessment. Regul. Toxicol. Pharmacol. 2013, 67:506-530.
93. Schultz T.W., Yarbrough J.W., Johnson E.L. Structure-activity relationships for reactivity of carbonyl compounds with glutathione. SAR QSAR Environ. Res. 2005, 16:313-322.
94. Shah I., Houck K., Judson R.S., Kavlock R.J., Martin M.T., Reif D.M., Wambaugh J., Dix D.J. Using nuclear receptor activity to stratify hepatocarcinogens. PLoS ONE 2011, 6:e14584. 10.1371/journal.pone.0014584.
95. Sheikh-Bahaei S., Maher J.J., Hunt C.A. Computational experiments reveal plausible mechanisms for changing patterns of hepatic zonation of xenobiotic clearance and hepatotoxicity. J. Theor. Biol. 2010, 265:718-733.
96. Simon T., Aylward L.L., Kirman C.R., Rowlands J.C., Budinsky R.A. Estimates of cancer potency of 2,3,7,8-tetrachlorodibenzo(p)dioxin using linear and nonlinear dose-response modeling and toxicokinetics. Toxicol. Sci. 2009, 112:490-506.
97. Simon T., Stoney Simons S., Preston R.J., Boobis A.R., Cohen S.M., Doerrer N.G., Fenner-Crisp P.A., McMullin T., McQueen C.A., Rowlands J.C. The use of mode of action information in risk assessment: quantitative key events/dose-response framework for modeling the dose-response for key events. Crit. Rev. Toxicol. 2014, in press.
98. Teeguarden J., Hanson-Drury S., Fisher J.W., Doerge D.R. Are typical human serum BPA concentrations measurable and sufficient to be estrogenic in the general population?. Food Chem. Toxicol. 2013, 62:949-963. 10.1016/j.fct.2013.08.001.
99. Teeguarden J.G., Calafat A.M., Ye X., Doerge D.R., Churchwell M.I., Gunawan R., Graham M.K. Twenty-four hour human urine and serum profiles of bisphenol a during high-dietary exposure. Toxicol. Sci. 2011, 123:48-57. 10.1093/toxsci/kfr160.
100. Teeguarden J.G., Hanson-Drury S. A systematic review of Bisphenol A "low dose" studies in the context of human exposure: a case for establishing standards for reporting "low-dose" effects of chemicals. Food Chem. Toxicol. 2013, 62:935-948. 10.1016/j.fct.2013.07.007.
101. Thomas R.S., Black M., Li L., Healy E., Chu T.-M., Bao W., Andersen M., Wolfinger R. A comprehensive statistical analysis of predicting in vivo hazard using high-throughput in vitro screening. Toxicol. Sci. 2012, 10.1093/toxsci/kfs159.
102. Thomas R.S., Philbert M.A., Auerbach S.S., Wetmore B.A., Devito M.J., Cote I., Rowlands J.C., Whelan M.P., Hays S.M., Andersen M.E., Meek M.E.B., Reiter L.W., Lambert J.C., Clewell H.J., Stephens M.L., Zhao Q.J., Wesselkamper S.C., Flowers L., Carney E.W., Pastoor T.P., Petersen D.D., Yauk C.L., Nong A. Incorporating new technologies into toxicity testing and risk assessment: moving from 21st century vision to a data-driven framework. Toxicol. Sci. 2013, 136:4-18. 10.1093/toxsci/kft178.
103. Tluczkiewicz I., Batke M., Kroese D., Buist H., Aldenberg T., Pauné E., Grimm H., Kühne R., Schüürmann G., Mangelsdorf I., Escher S.E. The OSIRIS weight of evidence approach: ITS for the endpoints repeated-dose toxicity (RepDose ITS). Regul. Toxicol. Pharmacol. 2013, 67:157-169. 10.1016/j.yrtph.2013.02.004.
104. Tollefsen K.E., Scholz S., Cronin M.T., Edwards S.W., de Knecht J., Crofton K., Garcia-Reyero N., Hartung T., Worth A., Patlewicz G. Applying adverse outcome pathways (AOPs) to support integrated approaches to testing and assessment (IATA). Regul. Toxicol. Pharmacol. 2014, (pii: S0273-2300(14)00214-1). 10.1016/j.yrtph.2014.09.009.
105. Tonnelier A., Coecke S., Zaldívar J.-M. Screening of chemicals for human bioaccumulative potential with a physiologically based toxicokinetic model. Arch. Toxicol. 2011, 10.1007/s00204-011-0768-0.
106. Urbisch D., Mehling A., Guth K., Ramirez T., Honarvar N., Kolle S., Landsiedel R., Jaworska J., Kern P.S., Gerberick F., Natsch A., Emter R., Ashikaga T., Miyazawa M., Sakaguchi H. Assessing skin sensitization hazard in mice and men using non-animal test methods. Regul. Toxicol. Pharmacol. 2014, (pii: S0273-2300(14)00309-2). 10.1016/j.yrtph.2014.12.008.
107. van der Veen J.W., Rorije E., Emter R., Natsch A., van Loveren H., Ezendam J. Evaluating the performance of integrated approaches for hazard identification of skin sensitizing chemicals. Regul. Toxicol. Pharmacol. 2014, 2014(69):371-379.
108. van Leeuwen K., Schultz T.W., Henry T., Diderich B., Veith G.D. Using chemical categories to fill data gaps in hazard assessment. SAR QSAR Environ. Res. 2009, 20:207-220.
109. Vezin C.M., Walker N.J., Olson J.R. Subchronic exposure to TCDD, PeCDF, PCB 126 and PCB 153: effect on hepatic gene expression. Environ. Health Perspect. 2004, 112:1636-1644.
110. Vinken M. The adverse outcome pathway concept: a pragmatic tool in toxicology. Toxicology 2013, 312:158-165. 10.1016/j.tox.2013.08.011.
111. Wambaugh J.F., Setzer R.W., Reif D.M., Gangwal S., Mitchell-Blackwood J., Arnot J.A., Joliet O., Frame A., Rabinowitz J., Knudsen T.B., Judson R.S., Egeghy P., Vallero D., Cohen Hubal E.A. High-throughput models for exposure-based chemical prioritization in the ExpoCast project. Environ. Sci. Technol. 2013, 47:8479-8488.
112. Yao C.Q., Prokopec S.D., Watson J.D., Pang R., P'ng C., Chong L.C., Harding N.J., Pohjanvirta R., Okey A.B., Boutros P.C. Inter-strain heterogeneity in rat hepatic transcriptomic responses to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Toxicol. Appl. Pharmacol. 2012, 260:135-145.
113. Wetmore B.A., Wambaugh J.F., Ferguson S.S., Sochaski M.A., Rotroff D.M., Freeman K., Clewell H.J., Dix D.J., Andersen M.E., Houck K.A., Allen B., Judson R.S., Singh R., Kavlock R.J., Richard A.M., Thomas R.S. Integration of dosimetry, exposure and high-throughput screening data in chemical toxicity assessment. Toxicol. Sci. 2011, 125:157-174. 10.1093/toxsci/kfr254.
114. Zhao Y.Y.I., Tao F.M., Zeng E.Y. Theoretical study of the quantitative structure-activity relationships for the toxicity of dibenzo-p-dioxins. Chemosphere 2008, 73:86-91.